{"id":986265,"date":"2026-07-29T07:06:23","date_gmt":"2026-07-29T11:06:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies\/"},"modified":"2026-07-29T07:06:23","modified_gmt":"2026-07-29T11:06:23","slug":"tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies\/","title":{"rendered":"TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2\u2122, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies\u00a0"},"content":{"rendered":"<h2>\nActively enrolling patients across the US with anticipated topline data readout mid-2028<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">WALTHAM, Mass., July  29, 2026  (GLOBE NEWSWIRE) &#8212; TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the first patient has been infused with TSC-101 in the pivotal Phase 3 ALLOHA-2\u2122 trial (NCT07702578). The patient, who was enrolled in June, has now received their first infusion of TSC-101 following successful stem cell engraftment. The trial is investigating the efficacy and safety of TSC-101 for the treatment of residual disease to prevent relapse following allogeneic hematopoietic cell transplantation (allo-HCT) in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).<\/p>\n<p align=\"justify\">\u201cDosing our first patient in the ALLOHA-2\u2122 study is a significant milestone for TScan. Having been a part of TScan as we moved TSC-101 from an idea to Discovery, through Phase 1 clinical development, and now to a Phase 3 study, I want to acknowledge all the hard work that went into bringing TSC-101 to this integral step and congratulate all current and previous members of the TScan team,\u201d said Gavin MacBeath, Ph.D., Chief Executive Officer. \u201cI would also like to thank the investigators, the patients, and their families for participating in our Phase 1 ALLOHA\u2122 trial. In June, we reported initial data from Cohort C of that study, in which patients were treated with our commercial-ready manufacturing process. The strong clinical efficacy and positive safety profile observed in this cohort gives us added confidence in our Phase 3 trial and future clinical development plans.\u201d<\/p>\n<p align=\"justify\">\u201cTSC-101 has demonstrated a safety profile and clinical results that continue to excite the transplant community,\u201d said Chrystal U. Louis, M.D., Chief Medical Officer. \u201cThe pace of Cohort C enrollment highlights the growing interest in TSC-101 as a potential therapeutic option for people with AML or MDS, and we look forward to working with our investigators to address residual disease and improve survival in patients after allo-HCT.\u201d<\/p>\n<p align=\"justify\">The Phase 3 ALLOHA-2\u2122 pivotal trial is a study evaluating TSC-101 administered after standard of care HCT vs HCT alone in patients with AML or MDS. Treatment is based on biological assignment (genetic randomization), with A*02:01-positive subjects with an appropriate donor assigned to the treatment arm, and A*02:01-negative subjects, or A*02:01-posititve subjects without an appropriate donor, assigned to the control arm. All subjects will receive HCT with reduced intensity conditioning. Subjects in the treatment arm will receive two infusions of TSC-101 following engraftment. The primary endpoint for the study is relapse-free survival, and key secondary endpoints include overall survival and event-free survival.<\/p>\n<p align=\"justify\">To learn more about the ALLOHA-2\u2122 clinical trial, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UXI-0clSjjDKOuXaK2Con1euol9bkfqDezanaWdFENATK3p2GJXx6WENH_8mTHvc3cDlVWXjlqDoUatRS3Ke0hhePifKNnCotqCr8MKt8JGKcLSoCz5uT0n2Uwli9spD\" rel=\"nofollow\" target=\"_blank\">clinicaltrials.gov<\/a> (identifier: NCT07702578).<\/p>\n<p align=\"justify\">\n        <strong>About TScan Therapeutics, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company\u2019s lead TCR-T therapy candidate, TSC-101, is in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA-2\u2122 Phase 3 pivotal trial). The Company is also in early stages of developing methods for in vivo engineering to treat solid tumors. In addition, the Company is applying its target discovery platform to discover novel targets in various T cell-mediated autoimmune disorders.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding TScan Therapeutics, Inc.\u2019s (\u201cTScan\u201d or the \u201cCompany\u201d) plans, progress, expectations, and timing relating to the Company\u2019s hematologic malignancies program, including clinical updates of the ALLOHA-2<sup>TM<\/sup>\u00a0clinical trial, presentation of data, enrollment and dosing of patients, and market opportunities; the progress of the hematologic malignancies program being indicative or predictive of the success of such program; the structure, timing and success of the ALLOHA-2<sup>TM<\/sup> clinical trial; the potential benefits of any of the Company\u2019s proprietary platforms or current or future product candidates in treating patients; and the Company\u2019s goals, strategy and anticipated financial performance. TScan intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as, but not limited to, \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cobjective,\u201d \u201cintend,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201ccan,\u201d \u201cwould,\u201d \u201cexpect,\u201d \u201cbelieve,\u201d \u201canticipate,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201cdesign,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201cplan,\u201d \u201con track,\u201d or similar expressions or the negative of those terms. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions, and uncertainties. The express or implied forward-looking statements included in this release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: the beneficial characteristics, safety, efficacy, therapeutic effects and potential advantages of TScan\u2019s TCR-T therapy product candidates; TScan\u2019s expectations regarding its preclinical studies being predictive of clinical trial results; TScan\u2019s approved INDs being indicative or predictive of bringing TScan closer to its goal of providing customized TCR-T therapies to treat patients with cancer; the timing of the launch, initiation, progress, expected results and announcements of TScan\u2019s preclinical studies, clinical trials and its research and development programs; TScan\u2019s ability to enroll patients for its clinical trials within its expected timeline; TScan\u2019s plans relating to developing and commercializing its TCR-T therapy product candidates, if approved, including sales strategy; estimates of the size of the addressable market for TScan\u2019s TCR-T therapy product candidates; TScan\u2019s manufacturing capabilities and the scalable nature of its manufacturing process; TScan\u2019s estimates regarding expenses, future milestone payments and revenue, capital requirements and needs for additional financing; TScan\u2019s expectations regarding competition; TScan\u2019s anticipated growth strategies; TScan\u2019s ability to attract or retain key personnel; TScan\u2019s ability to establish and maintain development partnerships and collaborations; TScan\u2019s expectations regarding federal, state and foreign regulatory requirements; TScan\u2019s ability to obtain and maintain intellectual property protection for its proprietary platform technology and our product candidates; the sufficiency of TScan\u2019s existing capital resources to fund its future operating expenses and capital expenditure requirements; and other factors that are described in the \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations\u201d sections of TScan\u2019s most recent Annual Report on Form 10-K and any other filings that TScan has made or may make with the SEC in the future. Any forward-looking statements contained in this release represent TScan\u2019s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, TScan explicitly disclaims any obligation to update any forward-looking statements.<\/p>\n<p align=\"justify\">\n        <strong>Investor and Media Contact<\/strong>\n      <\/p>\n<p>Caileigh Dougherty<br \/>AVP, Head of Corporate Communications &amp; Investor Relations <br \/>857-399-9890<br \/>cdougherty@tscan.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMDAxOSM3NzQ4NjE2IzIyMDcwNjk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YTk2NTEyNTEtYWNkOS00N2FlLThjODEtNGYxMzliOTNkOTIwLTEyMTg2MjItMjAyNi0wNy0yOS1lbg==\/tiny\/TScan-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Actively enrolling patients across the US with anticipated topline data readout mid-2028 WALTHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) &#8212; TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the first patient has been infused with TSC-101 in the pivotal Phase 3 ALLOHA-2\u2122 trial (NCT07702578). The patient, who was enrolled in June, has now received their first infusion of TSC-101 following successful stem cell engraftment. The trial is investigating the efficacy and safety of TSC-101 for the treatment of residual disease to prevent relapse following allogeneic hematopoietic cell transplantation (allo-HCT) in patients with acute myeloid leukemia (AML) &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2\u2122, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies\u00a0&#8220;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-986265","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2\u2122, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies\u00a0 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2\u2122, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies\u00a0 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Actively enrolling patients across the US with anticipated topline data readout mid-2028 WALTHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) &#8212; TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the first patient has been infused with TSC-101 in the pivotal Phase 3 ALLOHA-2\u2122 trial (NCT07702578). The patient, who was enrolled in June, has now received their first infusion of TSC-101 following successful stem cell engraftment. The trial is investigating the efficacy and safety of TSC-101 for the treatment of residual disease to prevent relapse following allogeneic hematopoietic cell transplantation (allo-HCT) in patients with acute myeloid leukemia (AML) &hellip; Continue reading &quot;TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2\u2122, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies\u00a0&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-29T11:06:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMDAxOSM3NzQ4NjE2IzIyMDcwNjk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2\u2122, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies\u00a0\",\"datePublished\":\"2026-07-29T11:06:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies\\\/\"},\"wordCount\":1168,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMDAxOSM3NzQ4NjE2IzIyMDcwNjk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies\\\/\",\"name\":\"TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2\u2122, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies\u00a0 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMDAxOSM3NzQ4NjE2IzIyMDcwNjk=\",\"datePublished\":\"2026-07-29T11:06:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMDAxOSM3NzQ4NjE2IzIyMDcwNjk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMDAxOSM3NzQ4NjE2IzIyMDcwNjk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2\u2122, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2\u2122, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies\u00a0 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies\/","og_locale":"en_US","og_type":"article","og_title":"TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2\u2122, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies\u00a0 - Market Newsdesk","og_description":"Actively enrolling patients across the US with anticipated topline data readout mid-2028 WALTHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) &#8212; TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the first patient has been infused with TSC-101 in the pivotal Phase 3 ALLOHA-2\u2122 trial (NCT07702578). The patient, who was enrolled in June, has now received their first infusion of TSC-101 following successful stem cell engraftment. The trial is investigating the efficacy and safety of TSC-101 for the treatment of residual disease to prevent relapse following allogeneic hematopoietic cell transplantation (allo-HCT) in patients with acute myeloid leukemia (AML) &hellip; Continue reading \"TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2\u2122, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies\u00a0\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-29T11:06:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMDAxOSM3NzQ4NjE2IzIyMDcwNjk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2\u2122, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies\u00a0","datePublished":"2026-07-29T11:06:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies\/"},"wordCount":1168,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMDAxOSM3NzQ4NjE2IzIyMDcwNjk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies\/","name":"TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2\u2122, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies\u00a0 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMDAxOSM3NzQ4NjE2IzIyMDcwNjk=","datePublished":"2026-07-29T11:06:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMDAxOSM3NzQ4NjE2IzIyMDcwNjk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMDAxOSM3NzQ4NjE2IzIyMDcwNjk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2\u2122, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/986265","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=986265"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/986265\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=986265"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=986265"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=986265"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}